BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kilgour E, Rothwell DG, Brady G, Dive C. Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. Cancer Cell 2020;37:485-95. [PMID: 32289272 DOI: 10.1016/j.ccell.2020.03.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu L, Zhou Y, Chen L, Bissessur AS, Chen J, Mao M, Ju S, Chen L, Chen C, Li Z, Zhang X, Chen F, Cao F, Wang L, Wang Q. Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine. Front Cell Dev Biol 2021;9:744990. [PMID: 34957093 DOI: 10.3389/fcell.2021.744990] [Reference Citation Analysis]
2 Yang W, Fan L, Guo Z, Wu H, Chen J, Liu C, Yan Y, Ding S. Reversible capturing and voltammetric determination of circulating tumor cells using two-dimensional nanozyme based on PdMo decorated with gold nanoparticles and aptamer. Mikrochim Acta 2021;188:319. [PMID: 34476628 DOI: 10.1007/s00604-021-04927-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Palaz F, Kalkan AK, Can Ö, Demir AN, Tozluyurt A, Özcan A, Ozsoz M. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research. ACS Synth Biol 2021;10:1245-67. [PMID: 34037380 DOI: 10.1021/acssynbio.1c00107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Truong TH, Benner EA, Hagen KM, Temiz NA, Kerkvliet CP, Wang Y, Cortes-Sanchez E, Yang CH, Trousdell MC, Pengo T, Guillen KP, Welm BE, Dos Santos CO, Telang S, Lange CA, Ostrander JH. PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer. Oncogene 2021;40:4384-97. [PMID: 34103681 DOI: 10.1038/s41388-021-01871-w] [Reference Citation Analysis]
5 Londra D, Mastoraki S, Bournakis E, Zavridou M, Thanos A, Rampias T, Lianidou ES. USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer. Cancers (Basel) 2021;13:4607. [PMID: 34572834 DOI: 10.3390/cancers13184607] [Reference Citation Analysis]
6 Zhang L, Parvin R, Fan Q, Ye F. Emerging digital PCR technology in precision medicine. Biosensors and Bioelectronics 2022;211:114344. [DOI: 10.1016/j.bios.2022.114344] [Reference Citation Analysis]
7 Nordgård O, Brendsdal Forthun R, Lapin M, Grønberg BH, Kalland KH, Kopperud RK, Thomsen LCV, Tjensvoll K, Gilje B, Gjertsen BT, Hovland R. Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. Cancers (Basel) 2021;13:1861. [PMID: 33924696 DOI: 10.3390/cancers13081861] [Reference Citation Analysis]
8 Labib M, Kelley SO. Circulating tumor cell profiling for precision oncology. Mol Oncol 2021;15:1622-46. [PMID: 33448107 DOI: 10.1002/1878-0261.12901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Meng Y, Bian L, Zhang M, Bo F, Lu X, Li D. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs. Biomark Med 2020;14:1393-404. [PMID: 33073579 DOI: 10.2217/bmm-2020-0022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lu Y, Zheng Y, Wang Y, Gu D, Zhang J, Liu F, Chen K, Guo L. FlowCell-enriched circulating tumor cells as a predictor of lung cancer metastasis. Hum Cell 2021;34:945-51. [PMID: 33580470 DOI: 10.1007/s13577-021-00500-8] [Reference Citation Analysis]
11 Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki S, Resi MV, Tiné M, Pasello G, Hofman P. Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. IJMS 2022;23:4164. [DOI: 10.3390/ijms23084164] [Reference Citation Analysis]
12 Ribeiro MFSA, Knebel FH, Bettoni F, Saddi R, Sacardo KP, Canedo FSNA, Alessi JVM, Shimada AK, Marin JFG, Camargo AA, Katz A. Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. NPJ Precis Oncol 2021;5:5. [PMID: 33580193 DOI: 10.1038/s41698-021-00149-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zhou E, Li Y, Wu F, Guo M, Xu J, Wang S, Tan Q, Ma P, Song S, Jin Y. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine 2021;67:103365. [PMID: 33971402 DOI: 10.1016/j.ebiom.2021.103365] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Koh Y, Nakano K, Katayama K, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T, Hatano K, Kawashima A, Ujike T, Imamura R, Yamaguchi R, Imoto S, Shiotsu Y, Nonomura N, Uemura M. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. Int J of Urology. [DOI: 10.1111/iju.14816] [Reference Citation Analysis]
15 Muffly L, Sundaram V, Chen C, Yurkiewicz I, Kuo E, Burnash S, Spiegel JY, Arai S, Frank MJ, Johnston LJ, Lowsky R, Meyer EH, Negrin RS, Rezvani AR, Sidana S, Shiraz P, Shizuru JA, Weng WK, Liedtke M, Vempaty HT, Miklos DB. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv 2021;5:3147-51. [PMID: 34424318 DOI: 10.1182/bloodadvances.2021004234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tian X, Ge D, Zhang F, Zhang B, Bai W, Xu X, Li Z, Cao Y, Li P, Zou K, Zou L. Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. Int J Cancer 2021;148:921-31. [PMID: 33113150 DOI: 10.1002/ijc.33362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol 2021;18:297-312. [PMID: 33473219 DOI: 10.1038/s41571-020-00457-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 38.0] [Reference Citation Analysis]
18 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Reference Citation Analysis]
19 Balasaheb Mali S, Dahivelkar S. Liquid biopsy = Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis. Oral Oncol 2021;123:105588. [PMID: 34744021 DOI: 10.1016/j.oraloncology.2021.105588] [Reference Citation Analysis]
20 García-pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. [DOI: 10.1038/s41416-022-01776-9] [Reference Citation Analysis]
21 Vasantharajan SS, Eccles MR, Rodger EJ, Pattison S, McCall JL, Gray ES, Calapre L, Chatterjee A. The Epigenetic landscape of Circulating tumour cells. Biochim Biophys Acta Rev Cancer 2021;1875:188514. [PMID: 33497709 DOI: 10.1016/j.bbcan.2021.188514] [Reference Citation Analysis]
22 Lam KK, Thean LF, Cheah PY. Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. Int J Biochem Cell Biol 2021;137:106032. [PMID: 34182137 DOI: 10.1016/j.biocel.2021.106032] [Reference Citation Analysis]
23 Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 2022. [PMID: 35264777 DOI: 10.1038/s41568-022-00454-5] [Reference Citation Analysis]
24 Hofman P. What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy. JMP 2021;2:147-72. [DOI: 10.3390/jmp2020015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
25 Jung D, Jain P, Yao Y, Wang M. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol 2020;13:127. [PMID: 32972438 DOI: 10.1186/s13045-020-00961-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Borum RM, Moore C, Chan SK, Steinmetz NF, Jokerst JV. A Photoacoustic Contrast Agent for miR-21 via NIR Fluorescent Hybridization Chain Reaction. Bioconjug Chem 2021. [PMID: 34406744 DOI: 10.1021/acs.bioconjchem.1c00375] [Reference Citation Analysis]
27 Baltagiannis EG, Ziogas DE, Cho WC, Mitsis M, Roukos DH. Tumor heterogeneity-driven individualized therapy. Future Oncol 2021;17:235-40. [PMID: 33305621 DOI: 10.2217/fon-2020-0915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Rabas N, Palmer S, Mitchell L, Ismail S, Gohlke A, Riley JS, Tait SWG, Gammage P, Soares LL, Macpherson IR, Norman JC. PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. J Cell Biol 2021;220:e202006049. [PMID: 34623384 DOI: 10.1083/jcb.202006049] [Reference Citation Analysis]
29 Parisi A, Porzio G, Pulcini F, Cannita K, Ficorella C, Mattei V, Delle Monache S. What Is Known about Theragnostic Strategies in Colorectal Cancer. Biomedicines 2021;9:140. [PMID: 33535557 DOI: 10.3390/biomedicines9020140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Conteduca V, Casadei C, Scarpi E, Brighi N, Schepisi G, Lolli C, Gurioli G, Toma I, Poti G, Farolfi A, De Giorgi U. Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Cancers 2022;14:2219. [DOI: 10.3390/cancers14092219] [Reference Citation Analysis]
31 Martinez-Dominguez MV, Zottel A, Šamec N, Jovčevska I, Dincer C, Kahlert UD, Nickel AC. Current Technologies for RNA-Directed Liquid Diagnostics. Cancers (Basel) 2021;13:5060. [PMID: 34680210 DOI: 10.3390/cancers13205060] [Reference Citation Analysis]
32 Xu M, Liu W, Zou K, Wei S, Zhang X, Li E, Wang Q. Design and Clinical Application of an Integrated Microfluidic Device for Circulating Tumor Cells Isolation and Single-Cell Analysis. Micromachines (Basel) 2021;12:49. [PMID: 33401770 DOI: 10.3390/mi12010049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sahin KB, Shah ET, Ferguson GP, Molloy C, Kalita-de Croft P, Hayes SA, Hudson A, Colvin E, Kamitakahara H, Harvie R, Hasovits C, Khan T, Duijf PHG, Howell VM, He Y, Bolderson E, Hooper JD, Lakhani SR, Richard DJ, O'Byrne KJ, Adams MN. Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers (Basel) 2021;13:4651. [PMID: 34572879 DOI: 10.3390/cancers13184651] [Reference Citation Analysis]
34 Romano C, Martorana F, Pennisi MS, Stella S, Massimino M, Tirrò E, Vitale SR, Di Gregorio S, Puma A, Tomarchio C, Manzella L. Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer. Int J Mol Sci 2021;22:7707. [PMID: 34299334 DOI: 10.3390/ijms22147707] [Reference Citation Analysis]
35 Hata T, Mizuma M, Iseki M, Takadate T, Ishida M, Nakagawa K, Hayashi H, Morikawa T, Motoi F, Unno M. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. J Hepatobiliary Pancreat Sci 2021;28:648-58. [PMID: 34022116 DOI: 10.1002/jhbp.993] [Reference Citation Analysis]
36 Wang Y, Wang Z, Gang X, Wang G. Liquid biopsy in prostate cancer: current status and future challenges of clinical application. Aging Male 2021;24:58-71. [PMID: 34850655 DOI: 10.1080/13685538.2021.1944085] [Reference Citation Analysis]
37 Saha S, Allelein S, Pandey R, Medina-Perez P, Osman E, Kuhlmeier D, Soleymani L. Two-Step Competitive Hybridization Assay: A Method for Analyzing Cancer-Related microRNA Embedded in Extracellular Vesicles. Anal Chem 2021;93:15913-21. [PMID: 34806869 DOI: 10.1021/acs.analchem.1c03165] [Reference Citation Analysis]
38 Iliuk A, Wu X, Li L, Sun J, Hadisurya M, Boris RS, Tao WA. Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification. J Proteome Res 2020;19:2563-74. [PMID: 32396726 DOI: 10.1021/acs.jproteome.0c00151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hadjimichael AC, Pergaris A, Kaspiris A, Foukas AF, Theocharis SE. Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors. Int J Mol Sci 2021;22:11526. [PMID: 34768955 DOI: 10.3390/ijms222111526] [Reference Citation Analysis]
40 Spehner L, Boustani J, Cabel L, Doyen J, Vienot A, Borg C, Kim S. Present and Future Research on Anal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:3895. [PMID: 34359795 DOI: 10.3390/cancers13153895] [Reference Citation Analysis]
41 Cabel L, Bonneau C, Bernard-Tessier A, Héquet D, Tran-Perennou C, Bataillon G, Rouzier R, Féron JG, Fourchotte V, Le Brun JF, Benoît C, Rodrigues M, Scher N, Minsat M, Legrier ME, Bièche I, Proudhon C, Sastre-Garau X, Bidard FC, Jeannot E. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. ESMO Open 2021;6:100154. [PMID: 34022731 DOI: 10.1016/j.esmoop.2021.100154] [Reference Citation Analysis]
42 Kim S, Spehner L, Cabel L, Bidard FC, Borg C. [Squamous cell anal carcinoma. What's next ?]. Bull Cancer 2021;108:80-9. [PMID: 33423780 DOI: 10.1016/j.bulcan.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Lopes MB, Martins EP, Vinga S, Costa BM. The Role of Network Science in Glioblastoma. Cancers (Basel) 2021;13:1045. [PMID: 33801334 DOI: 10.3390/cancers13051045] [Reference Citation Analysis]
44 Ravensbergen CJ, Kuruc M, Polack M, Crobach S, Putter H, Gelderblom H, Roy D, Tollenaar RAEM, Mesker WE. The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer. Cancers (Basel) 2021;14:163. [PMID: 35008327 DOI: 10.3390/cancers14010163] [Reference Citation Analysis]
45 Louie AD, Huntington K, Carlsen L, Zhou L, El-Deiry WS. Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Front Pharmacol 2021;12:747194. [PMID: 34737704 DOI: 10.3389/fphar.2021.747194] [Reference Citation Analysis]
46 Guo H, Li W, Wang B, Chen N, Qian L, Cui J. Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer? Chin J Cancer Res 2021;33:574-82. [PMID: 34815631 DOI: 10.21147/j.issn.1000-9604.2021.05.04] [Reference Citation Analysis]
47 Izadmehr S, Lundon DJ, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani KK, Sfakianos JP, Tsao CK, Wiklund P, Oh WK, Cordon-Cardo C, Tewari AK, Galsky MD, Kyprianou N. The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Front Oncol 2021;11:734963. [PMID: 34646777 DOI: 10.3389/fonc.2021.734963] [Reference Citation Analysis]
48 Ravegnini G, De Iaco P, Gorini F, Dondi G, Klooster I, De Crescenzo E, Bovicelli A, Hrelia P, Perrone AM, Angelini S. Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision. Biomedicines 2021;9:1316. [PMID: 34680433 DOI: 10.3390/biomedicines9101316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Al-Qasem AJ, Alves CL, Ditzel HJ. Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers (Basel) 2021;13:5397. [PMID: 34771560 DOI: 10.3390/cancers13215397] [Reference Citation Analysis]
50 Kujala J, Hartikainen JM, Tengström M, Sironen R, Auvinen P, Kosma V, Mannermaa A. Circulating Cell-Free DNA Reflects the Clonal Evolution of Breast Cancer Tumors. Cancers 2022;14:1332. [DOI: 10.3390/cancers14051332] [Reference Citation Analysis]
51 He X, Zhong X, Hu Z, Zhao S, Wei P, Li D. An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications. Clin Transl Med 2020;10:e249. [PMID: 33377655 DOI: 10.1002/ctm2.249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
52 Hofman P. Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients. Cancers (Basel) 2021;13:2049. [PMID: 33922637 DOI: 10.3390/cancers13092049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
53 Yi Z, Qu C, Zeng Y, Liu Z. Liquid biopsy: early and accurate diagnosis of brain tumor. J Cancer Res Clin Oncol 2022. [PMID: 35451698 DOI: 10.1007/s00432-022-04011-3] [Reference Citation Analysis]
54 Zhou H, Zhu L, Song J, Wang G, Li P, Li W, Luo P, Sun X, Wu J, Liu Y, Zhu S, Zhang Y. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer 2022;21:86. [PMID: 35337361 DOI: 10.1186/s12943-022-01556-2] [Reference Citation Analysis]
55 Liu J, Lian J, Chen Y, Zhao X, Du C, Xu Y, Hu H, Rao H, Hong X. Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response. Front Genet 2021;12:734595. [PMID: 34512735 DOI: 10.3389/fgene.2021.734595] [Reference Citation Analysis]
56 Yang Z, Su H, You E, Liu S, Li Z, Zhang Y. High Uniformity and Enhancement Au@AgNS 3D Substrates for the Diagnosis of Breast Cancer. ACS Omega. [DOI: 10.1021/acsomega.2c01453] [Reference Citation Analysis]
57 Ortolan E, Appierto V, Silvestri M, Miceli R, Veneroni S, Folli S, Pruneri G, Vingiani A, Belfiore A, Cappelletti V, Vismara M, Dell'Angelo F, De Cecco L, Bianchi GV, de Braud FG, Daidone MG, Di Cosimo S. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. ESMO Open 2021;6:100086. [PMID: 33743331 DOI: 10.1016/j.esmoop.2021.100086] [Reference Citation Analysis]
58 Zavridou M, Strati A, Bournakis E, Smilkou S, Tserpeli V, Lianidou E. Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. Cancers (Basel) 2021;13:780. [PMID: 33668490 DOI: 10.3390/cancers13040780] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
59 Guo X, Gao S, Li Z, Hao J. The role of biomarker in pancreatic neuroendocrine tumor: a narrative review. Journal of Pancreatology 2021;Publish Ahead of Print. [DOI: 10.1097/jp9.0000000000000076] [Reference Citation Analysis]
60 Ye B, Li F, Chen M, Weng Y, Qi C, Xie Y, Zhang Q, Ding H, Zhang J, Gao X. A panel of platelet-associated circulating long non-coding RNAs as potential biomarkers for colorectal cancer. Genomics 2021;114:31-7. [PMID: 34843904 DOI: 10.1016/j.ygeno.2021.11.026] [Reference Citation Analysis]
61 Michela B. Liquid Biopsy: A Family of Possible Diagnostic Tools. Diagnostics (Basel) 2021;11:1391. [PMID: 34441325 DOI: 10.3390/diagnostics11081391] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Alba-Bernal A, Lavado-Valenzuela R, Domínguez-Recio ME, Jiménez-Rodriguez B, Queipo-Ortuño MI, Alba E, Comino-Méndez I. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine 2020;62:103100. [PMID: 33161226 DOI: 10.1016/j.ebiom.2020.103100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Li F, Xu H, Zhao Y. Magnetic particles as promising circulating tumor cell catchers assisting liquid biopsy in cancer diagnosis: A review. TrAC Trends in Analytical Chemistry 2021;145:116453. [DOI: 10.1016/j.trac.2021.116453] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Wu T, Jiang X, Zhang X, Wu B, Xu B, Liu X, Zheng L, Wang Y. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control 2021;28:1073274821989314. [PMID: 33618536 DOI: 10.1177/1073274821989314] [Reference Citation Analysis]
65 Dong X, Chang M, Song X, Ding S, Xie L, Song X. Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as potential biomarkers for early diagnosis of non-small cell lung cancer. Thorac Cancer 2021;12:539-48. [PMID: 33372399 DOI: 10.1111/1759-7714.13800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 Kim CJ, Dong L, Amend SR, Cho YK, Pienta KJ. The role of liquid biopsies in prostate cancer management. Lab Chip 2021. [PMID: 34346466 DOI: 10.1039/d1lc00485a] [Reference Citation Analysis]
67 Zhang W, Wei L, Huang J, Zhong B, Li J, Xu H, He S, Liu Y, Liu J, Lv H, Wang X. cfDNApipe: A comprehensive quality control and analysis pipeline for cell-free DNA high-throughput sequencing data. Bioinformatics 2021:btab413. [PMID: 34042972 DOI: 10.1093/bioinformatics/btab413] [Reference Citation Analysis]
68 Yeakel J, Kannan A, Rattigan NH, Yamamoto M, Aleshin A, Harris JP, Gao L. Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient. JAAD Case Rep 2021;18:94-8. [PMID: 34869814 DOI: 10.1016/j.jdcr.2021.10.025] [Reference Citation Analysis]
69 Zhang L, Loh XJ, Ruan J. Photoelectrochemical nanosensors: An emerging technique for tumor liquid biopsy. Journal of Photochemistry and Photobiology A: Chemistry 2022;429:113942. [DOI: 10.1016/j.jphotochem.2022.113942] [Reference Citation Analysis]
70 Lin Q, Fang X, Liang G, Luo Q, Cen Y, Shi Y, Jia S, Li J, Yang W, Sanders AJ, Gong C, Jiang W. Silencing CTNND1 Mediates Triple-Negative Breast Cancer Bone Metastasis via Upregulating CXCR4/CXCL12 Axis and Neutrophils Infiltration in Bone. Cancers (Basel) 2021;13:5703. [PMID: 34830862 DOI: 10.3390/cancers13225703] [Reference Citation Analysis]
71 Hofman P. Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice. Cells 2021;10:168. [PMID: 33467720 DOI: 10.3390/cells10010168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
72 Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 2021;137:1491-502. [PMID: 33512416 DOI: 10.1182/blood.2020007245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
73 Flores BCT, Correia MP, Rodríguez JG, Henrique R, Jerónimo C. Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer. Cancers (Basel) 2021;13:4209. [PMID: 34439363 DOI: 10.3390/cancers13164209] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Matsuda S, Kawakubo H, Irino T, Kitagawa Y. Role sharing between minimally invasive oesophagectomy and organ preservation approach for surgically resectable advanced oesophageal cancer. Jpn J Clin Oncol 2021:hyab192. [PMID: 34891170 DOI: 10.1093/jjco/hyab192] [Reference Citation Analysis]
75 Caputo V, De Falco V, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F, Martini G, Corte CMD, Ciardiello D, Poliero L, De Vita F, Orditura M, Fasano M, Franco R, Caraglia M, Avitabile A, Scalamogna R, Marchi B, Ciardiello F, Troiani T, Napolitano S. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther Adv Med Oncol 2022;14:175883592210968. [DOI: 10.1177/17588359221096878] [Reference Citation Analysis]
76 Wang SQ, Chai CX, Wang BR, Zhu F, Shang D, Li M. Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(1): 362-365 [DOI: 10.4251/wjgo.v14.i1.362] [Reference Citation Analysis]
77 Wei J, Wang Y, Gao J, Li Z, Pang R, Zhai T, Ma Y, Wang Z, Meng X. Detection of BRAFV600E mutation of thyroid cancer in circulating tumor DNA by an electrochemical-enrichment assisted ARMS-qPCR assay. Microchemical Journal 2022;179:107452. [DOI: 10.1016/j.microc.2022.107452] [Reference Citation Analysis]
78 García-Foncillas J, Argente J, Bujanda L, Cardona V, Casanova B, Fernández-Montes A, Horcajadas JA, Iñiguez A, Ortiz A, Pablos JL, Pérez Gómez MV. Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. Mol Diagn Ther 2021;25:563-76. [PMID: 34331269 DOI: 10.1007/s40291-021-00544-4] [Reference Citation Analysis]
79 Meng Y, Sun J, Zheng Y, Zhang G, Yu T, Piao H. Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies. Onco Targets Ther 2021;14:3417-28. [PMID: 34079287 DOI: 10.2147/OTT.S311907] [Reference Citation Analysis]
80 Coppola L, Cianflone A, Pane K, Franzese M, Mirabelli P, Salvatore M. The impact of different preanalytical methods related to CA 15-3 determination in frozen human blood samples: a systematic review. Syst Rev 2021;10:102. [PMID: 33836821 DOI: 10.1186/s13643-021-01631-7] [Reference Citation Analysis]
81 Salati M, Venetis K, Fassan M, Malapelle U, Pagni F, Sajjadi E, Fusco N, Ghidini M. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Future Oncol 2021;17:4607-18. [PMID: 34406032 DOI: 10.2217/fon-2021-0228] [Reference Citation Analysis]
82 Lyskjær I, Kara N, De Noon S, Davies C, Rocha AM, Strobl AC, Usher I, Gerrand C, Strauss SJ, Schrimpf D, von Deimling A, Beck S, Flanagan AM. Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. Eur J Cancer 2022;168:1-11. [PMID: 35421838 DOI: 10.1016/j.ejca.2022.03.002] [Reference Citation Analysis]
83 Duffy MJ, Crown J. Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer. JPM 2022;12:99. [DOI: 10.3390/jpm12010099] [Reference Citation Analysis]
84 Masmudi-Martín M, Zhu L, Sanchez-Navarro M, Priego N, Casanova-Acebes M, Ruiz-Rodado V, Giralt E, Valiente M. Brain metastasis models: What should we aim to achieve better treatments? Adv Drug Deliv Rev 2021;169:79-99. [PMID: 33321154 DOI: 10.1016/j.addr.2020.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Zhu G, Guo YA, Ho D, Poon P, Poh ZW, Wong PM, Gan A, Chang MM, Kleftogiannis D, Lau YT, Tay B, Lim WJ, Chua C, Tan TJ, Koo SL, Chong DQ, Yap YS, Tan I, Ng S, Skanderup AJ. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. Nat Commun 2021;12:2229. [PMID: 33850132 DOI: 10.1038/s41467-021-22463-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Porter RL, Matulonis UA. Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer. J Clin Oncol 2021;39:3651-5. [PMID: 34529504 DOI: 10.1200/JCO.21.01886] [Reference Citation Analysis]
87 Ntzifa A, Strati A, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. Sci Rep 2021;11:2313. [PMID: 33504904 DOI: 10.1038/s41598-021-82068-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
88 Hur JY, Lee KY. Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA. Cancers (Basel) 2021;13:3827. [PMID: 34359729 DOI: 10.3390/cancers13153827] [Reference Citation Analysis]
89 Zhao Q, Miao C, Lu Q, Wu W, He Y, Wu S, Liu H, Lian C. Clinical Significance of Monitoring Circulating Free DNA and Plasma Heat Shock Protein 90alpha in Patients with Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2021;13:2223-34. [PMID: 33707971 DOI: 10.2147/CMAR.S295927] [Reference Citation Analysis]
90 Balendran-Braun S, Kieler M, Liebmann-Reindl S, Unseld M, Bianconi D, W Prager G, Streubel B. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Cancer Manag Res 2021;13:6249-61. [PMID: 34393517 DOI: 10.2147/CMAR.S308029] [Reference Citation Analysis]